Furthermore, the SAM-competitive PRMT5 inhibitors CMP5 and HLCL61 were developed to suppress PRMT5 enzymatic activity in B-cell lymphoma and AML directly [28,29]. This evidence concerns the gene PRMT5 and B-cell non-Hodgkin lymphoma.